Literature DB >> 18209594

Clinical and laboratory characteristics of acute hepatitis C in patients with end-stage renal disease on hemodialysis.

Lara B Lemos1, Renata M Perez, Carla A L Matos, Ivonete S Silva, Antonio Eduardo B Silva, Maria Lucia G Ferraz.   

Abstract

BACKGROUND: Patients with end-stage renal disease (ESRD) undergoing hemodialysis are a risk group for hepatitis C virus (HCV) infection. The characteristics of acute hepatitis C infection in this population are not well known. GOALS: To evaluate the clinical and laboratory characteristics of acute hepatitis C in ESRD patients treated with hemodialysis. STUDY: ESRD patients on hemodialysis with acute hepatitis C, characterized by elevated alanine aminotransferase (ALT) followed by anti-HCV seroconversion were studied.
RESULTS: Thirty-six patients (58% females, 44+/-12 y), with a mean time on hemodialysis of 2 years, were included. Only 2 (6%) patients had jaundice. ALT elevation was observed in all patients. Median peak ALT was 4.7 x upper limit of normal. The median interval between ALT elevation and anti-HCV seroconversion was 1 month (0 to 8). None of the patients with detectable HCV-RNA showed spontaneous clearance of viremia within 12 weeks of follow-up. Three (8%) patients presented ALT elevation followed by anti-HCV seroconversion with undetectable HCV-RNA.
CONCLUSIONS: Acute hepatitis C is frequently asymptomatic in ESRD patients on hemodialysis and should be suspected in all patients presenting elevated ALT. Determination of HCV-RNA is important for the confirmation of infection. Anti-HCV seroconversion seems to occur early and spontaneous clearance of HCV-RNA is uncommon.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18209594     DOI: 10.1097/MCG.0b013e31802dc57f

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  4 in total

1.  Recognizing acute hepatitis C in hemodialysis patients.

Authors:  Resat Ozaras; Mesut Yilmaz; Birgul Mete; Aslihan Demirel; Veysel Tahan
Journal:  Dig Dis Sci       Date:  2008-04-13       Impact factor: 3.199

Review 2.  Management of hepatitis C in patients with chronic kidney disease.

Authors:  Roberto J Carvalho-Filho; Ana Cristina C A Feldner; Antonio Eduardo B Silva; Maria Lucia G Ferraz
Journal:  World J Gastroenterol       Date:  2015-01-14       Impact factor: 5.742

Review 3.  Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5.

Authors:  Chen-Hua Liu; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2022-07-25       Impact factor: 9.029

Review 4.  Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals.

Authors:  Soon Young Ko; Won Hyeok Choe
Journal:  Clin Mol Hepatol       Date:  2018-03-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.